Nolxado (Naloxone Hydrochloride, Oxycodone Hydrochloride)

Oxycodone acts as a mu‑opioid receptor agonist, binding to receptors in the central nervous system to produce analgesia. Naloxone, included in the same tablet, has very low oral absorption but blocks peripheral mu‑receptors, reducing opioid‑induced constipation and decreasing the likelihood of abuse when the tablet is tampered with.

The appropriate dose of Nolxado is individualized by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, age, renal and hepatic function, and overall clinical condition. No fixed dosing regimen is provided here; the prescriber sets the dosage and titration schedule.

Safety data for Nolxado in pregnancy and lactation are limited. Opioids can cross the placenta and may cause neonatal respiratory depression, while naloxone’s effects are less clear. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or breastfeeding patients.

To request Nolxado, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Standard oxycodone provides potent analgesia but carries a higher risk of constipation and abuse. Nolxado combines oxycodone with naloxone, which mitigates opioid‑induced bowel dysfunction and adds an abuse‑deterrent element, while delivering comparable pain relief in most patients.

Nolxado tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Nolxado is taken orally as a whole tablet. Patients should swallow the tablet with a full glass of water and may take it with or without food, following the prescribing clinician’s instructions regarding timing and frequency.

The most serious risks include respiratory depression, severe hypotension, allergic reactions such as anaphylaxis, hepatic dysfunction, and, in rare cases, opioid withdrawal symptoms if the formulation is misused. Immediate medical attention is required if any of these events occur.

Nolxado is contraindicated in patients with known hypersensitivity to oxycodone, naloxone, or any excipients, as well as those with severe respiratory depression, acute or severe asthma, and paralytic ileus. Caution is also advised for individuals with significant hepatic impairment or those taking prohibited concomitant medications.